Search Results 271-280 of 17409 for Mmol

1. A Study to Evaluate the Safety and Effectiveness of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer - Mayo Clinic

   HbA1c ≥ 8.0% (63.9 mmol/mol). Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding intramuscular ...

2. Bilirubin test - Mayo Clinic

   This test is commonly used to measure bilirubin levels in newborns with infant jaundice. Check for a blockage in the bile ducts in the liver or the gallbladder.

3. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant - Mayo Clinic

   Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has ...

4. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

   Hemoglobin ≥ 5.6 mmol/L (~ 9 g/dL);; Absolute neutrophil count (ANC) ≥ 1500/μL (1.5 x 10^9/L);; Platelet count ≥ 100 x10^9/L. Have an Eastern Cooperative ...

5. Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas - Mayo Clinic

   Hemoglobin >= 9 g/dL (5.6 mmol/L). Subjects may not have had a transfusion within 7 days of screening assessment. Platelets >= 100 X 10^9/L. Subjects may not ...

6. MELD (model for end-stage liver disease) score - Doctors & Departments - Mayo Clinic

   Mayo Clinic scientists, doctors and surgeons develop liver transplant insights and innovations that make transplants safer and available for more people. They ...

7. Sym021 in Combination with Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients with Advanced Biliary Tract Carcinomas - Mayo Clinic

   Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L*. Renal. Serum creatinine or measured or calculated creatinine clearance (CrCL)** ≤ 1.5 × upper limit of normal (ULN) ...

8. Study of CG0070 Given in Combination With Pembrolizumab, in Non Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin - Mayo Clinic

   Hemoglobin ≥ 8 g/dL or ≥ 4.96 mmol/L;; Platelet count ≥ 100,000 platelets/mm^3;; Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 30 mL/min for ...

9. Study Comparing CB-839 with Cabozantinib vs. Cabozantinib with Placebo in Patients with Metastatic Renal Cell Carcinoma - Mayo Clinic

   Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol) or 24-hour urine protein < 1 g. Reproductive Status. Female patients of childbearing ...

10. A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity - Mayo Clinic

    Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment);; Serum creatinine < 1.5 X institutional ...